title: 125Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up.
abstract: Data from 305 Japanese men with low-risk (n = 175) or intermediate-risk (n = 130) prostate cancer who underwent (125)I monotherapy were retrospectively analyzed. Of the 305 patients, 93 received hormonal therapy for a median of 6 months (range, 1-33 months) before implantation. The prescribed dose to the prostate plus 3- to 5-mm margin was set at 145 Gy. The mean dose to 90% of the prostate volume at 1 month (D90) and the prostate volume receiving at least 100% dose at 1 month (V100) were 173.4 Gy and 95.8%, respectively. The median follow-up was 66 months (range, 12-94 months). The 5-year biochemical non-evidence of disease rate was 95.5% (low-risk, 94.2%; intermediate-risk, 97.3%). The 5-year freedom from clinical failure rate was 98.9% (low-risk, 98.9%; intermediate-risk, 99.2%).The initial prostate-specific antigen level was identified as a significant predictive factor for biochemical recurrence (P = 0.029). The late Grade 3 genitourinary toxicity rate was 2.0%. No patients displayed late gastrointestinal toxicity of Grade 3 or worse. Monotherapy with (125)I showed excellent outcomes with limited morbidity for Japanese men with low- and intermediate-risk prostate cancer after 5 years of follow-up.
authors.affiliation: Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Japan.
authors.forename: Akane
authors.initials: A
authors.lastname: Sekiguchi
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Ishiyama
authors.forename: Takefumi
authors.initials: T
authors.lastname: Satoh
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tabata
authors.forename: Shouko
authors.initials: S
authors.lastname: Komori
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Tsumura
authors.forename: Shogo
authors.initials: S
authors.lastname: Kawakami
authors.forename: Itaru
authors.initials: I
authors.lastname: Soda
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Iwamura
authors.forename: Kazushige
authors.initials: K
authors.lastname: Hayakawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000401:mortality*; D015897:Comorbidity; D018572:Disease-Free Survival; D006801:Humans; D015994:Incidence; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007564:Japan / Q000453:epidemiology; D008297:Male; D052801:Male Urogenital Diseases / Q000401:mortality; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000401:mortality* / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000401:mortality*; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes
keywords: 125I; brachytherapy; low dose rate; monotherapy; prostate cancer